In August 2010, people who had received metal-on-metal artificial hips began to be concerned about their implanted devices. DePuy Orthopaedics, a subsidiary of Johnson & Johnson, had announced a recall of its ASR LX Acetabular hip system due to a higher than normal failure rate.

A Supreme Court ruling on June 23 reversed separate U.S. appeals court rulings that would have held generic drug manufacturers responsible for warning patients of safety label changes.

A new Swedish study has verified that antidepressants known as selective serotonin reuptake inhibitors (SSRIs) increase the risk for birth defects when taken by the mother during early pregnancy.

Recently, the Pennsylvania Appellate Court affirmed a $1.5 million compensatory and $8.6 million punitive award against Wyeth, a division of Pfizer, on behalf of a woman diagnosed with hormone positive breast cancer. Plaintiff Mary Daniel had taken Wyeth’s hormone pill, Prempro, for 18 months. The trial and appeal was handled by Plaintiff’s attorneys Zoe Littlepage and Rainey Booth. How does this most recent decision affect the track record in hormone replacement therapy (HRT) litigation against Wyeth, which has been going on for several years?

Nine people died and 10 more were sickened in six Alabama hospitals after receiving IV packs filled with nutritional supplements that were contaminated with a dangerous bacteria. The supplement packs were compounded by a Birmingham pharmacy called Meds IV. Beasley Allen attorneys are investigating claims related to patient deaths as a result of receiving the tainted IV fluids.

It was announced this weekend that federal cases involving defective hip implant parts manufactured by DePuy Orthopaedics, a subsidiary of Johnson & Johnson, will be consolidated in federal court in the Northern District of Ohio under U.S. District Judge David A. Katz. The hip implant parts were recalled August 26 after research indicated patients who received the parts required a much higher than usual rate of revision surgeries.

The U.S. Food and Drug Administration has announced that Xanodyne Pharmaceuticals, inc., the maker of prescription pain medications Darvon and Darvocet, has agreed to withdraw the medications from the U.S. market. The move comes after the results of an FDA study in which new clinical data shows the drug, which goes by the generic name propoxyphene, puts patients at risk of potentially serious or even fatal heart rhythm abnormalities. The FDA determined the new data shows the risks of the drug outweigh any benefits.

Potent pain patches used to treat breakthrough pain in cancer patients already on around-the-clock pain medication are being recalled by the manufacturer because the patches may release too much of the painkiller Fentanyl which can lead to serious adverse events including death.

Potent pain patches used to treat breakthrough pain in cancer patients already on around-the-clock pain medication are being recalled by the manufacturer because the patches may release too much of the painkiller Fentanyl which can lead to serious adverse events including death.

Nearly 128,000 bottles of Tylenol have been recalled by manufacturer Johnson & Johnson after consumers reported a moldy odor in the product. This is just the latest in a long string of over-the-counter medication recalls by J&J for similar problems.